These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 11910361)

  • 1. p16 inactivation by methylation of the CDKN2A promoter occurs early during neoplastic progression in Barrett's esophagus.
    Bian YS; Osterheld MC; Fontolliet C; Bosman FT; Benhattar J
    Gastroenterology; 2002 Apr; 122(4):1113-21. PubMed ID: 11910361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p16INK4a promoter is hypermethylated at a high frequency in esophageal adenocarcinomas.
    Wong DJ; Barrett MT; Stöger R; Emond MJ; Reid BJ
    Cancer Res; 1997 Jul; 57(13):2619-22. PubMed ID: 9205067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p16 expression in Barrett's esophagus and esophageal adenocarcinoma: association with genetic and epigenetic alterations.
    Hardie LJ; Darnton SJ; Wallis YL; Chauhan A; Hainaut P; Wild CP; Casson AG
    Cancer Lett; 2005 Jan; 217(2):221-30. PubMed ID: 15617840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. INK4a-ARF alterations in Barrett's epithelium, intraepithelial neoplasia and Barrett's adenocarcinoma.
    Vieth M; Schneider-Stock R; Röhrich K; May A; Ell C; Markwarth A; Roessner A; Stolte M; Tannapfel A
    Virchows Arch; 2004 Aug; 445(2):135-41. PubMed ID: 15185075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypermethylation of the AKAP12 promoter is a biomarker of Barrett's-associated esophageal neoplastic progression.
    Jin Z; Hamilton JP; Yang J; Mori Y; Olaru A; Sato F; Ito T; Kan T; Cheng Y; Paun B; David S; Beer DG; Agarwal R; Abraham JM; Meltzer SJ
    Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):111-7. PubMed ID: 18199717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk.
    Schulmann K; Sterian A; Berki A; Yin J; Sato F; Xu Y; Olaru A; Wang S; Mori Y; Deacu E; Hamilton J; Kan T; Krasna MJ; Beer DG; Pepe MS; Abraham JM; Feng Z; Schmiegel W; Greenwald BD; Meltzer SJ
    Oncogene; 2005 Jun; 24(25):4138-48. PubMed ID: 15824739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue.
    Galipeau PC; Prevo LJ; Sanchez CA; Longton GM; Reid BJ
    J Natl Cancer Inst; 1999 Dec; 91(24):2087-95. PubMed ID: 10601379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CDKN2A-p16 Deletion and Activated KRAS
    Sun J; Sepulveda JL; Komissarova EV; Hills C; Seckar TD; LeFevre NM; Simonyan H; Young C; Su G; Del Portillo A; Wang TC; Sepulveda AR
    Cell Mol Gastroenterol Hepatol; 2024; 17(5):769-784. PubMed ID: 38296052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concordant loss of MTAP and p16/CDKN2A expression in gastroesophageal carcinogenesis: evidence of homozygous deletion in esophageal noninvasive precursor lesions and therapeutic implications.
    Powell EL; Leoni LM; Canto MI; Forastiere AA; Iocobuzio-Donahue CA; Wang JS; Maitra A; Montgomery E
    Am J Surg Pathol; 2005 Nov; 29(11):1497-504. PubMed ID: 16224217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypermethylation of the CDKN2/p16 promoter during neoplastic progression in Barrett's esophagus.
    Klump B; Hsieh CJ; Holzmann K; Gregor M; Porschen R
    Gastroenterology; 1998 Dec; 115(6):1381-6. PubMed ID: 9834265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methylation of APC, TIMP3, and TERT: a new predictive marker to distinguish Barrett's oesophagus patients at risk for malignant transformation.
    Clément G; Braunschweig R; Pasquier N; Bosman FT; Benhattar J
    J Pathol; 2006 Jan; 208(1):100-7. PubMed ID: 16278815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA promoter hypermethylation of p16 and APC predicts neoplastic progression in Barrett's esophagus.
    Wang JS; Guo M; Montgomery EA; Thompson RE; Cosby H; Hicks L; Wang S; Herman JG; Canto MI
    Am J Gastroenterol; 2009 Sep; 104(9):2153-60. PubMed ID: 19584833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative analysis of p16 methylation in Barrett's carcinogenesis.
    Chueca E; Valero A; Hördnler C; Puertas A; Carrera P; García-González MA; Strunk M; Lanas A; Piazuelo E
    Ann Diagn Pathol; 2020 Aug; 47():151554. PubMed ID: 32570024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium.
    Wong DJ; Paulson TG; Prevo LJ; Galipeau PC; Longton G; Blount PL; Reid BJ
    Cancer Res; 2001 Nov; 61(22):8284-9. PubMed ID: 11719461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequent methylation of eyes absent 4 gene in Barrett's esophagus and esophageal adenocarcinoma.
    Zou H; Osborn NK; Harrington JJ; Klatt KK; Molina JR; Burgart LJ; Ahlquist DA
    Cancer Epidemiol Biomarkers Prev; 2005 Apr; 14(4):830-4. PubMed ID: 15824152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma.
    Galipeau PC; Li X; Blount PL; Maley CC; Sanchez CA; Odze RD; Ayub K; Rabinovitch PS; Vaughan TL; Reid BJ
    PLoS Med; 2007 Feb; 4(2):e67. PubMed ID: 17326708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma.
    Eads CA; Lord RV; Kurumboor SK; Wickramasinghe K; Skinner ML; Long TI; Peters JH; DeMeester TR; Danenberg KD; Danenberg PV; Laird PW; Skinner KA
    Cancer Res; 2000 Sep; 60(18):5021-6. PubMed ID: 11016622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aberrant methylation of secreted frizzled-related protein genes in esophageal adenocarcinoma and Barrett's esophagus.
    Zou H; Molina JR; Harrington JJ; Osborn NK; Klatt KK; Romero Y; Burgart LJ; Ahlquist DA
    Int J Cancer; 2005 Sep; 116(4):584-91. PubMed ID: 15825175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LOH at the sites of the DCC, APC, and TP53 tumor suppressor genes occurs in Barrett's metaplasia and dysplasia adjacent to adenocarcinoma of the esophagus.
    Dolan K; Garde J; Walker SJ; Sutton R; Gosney J; Field JK
    Hum Pathol; 1999 Dec; 30(12):1508-14. PubMed ID: 10667431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypermethylation and loss of expression of glutathione peroxidase-3 in Barrett's tumorigenesis.
    Lee OJ; Schneider-Stock R; McChesney PA; Kuester D; Roessner A; Vieth M; Moskaluk CA; El-Rifai W
    Neoplasia; 2005 Sep; 7(9):854-61. PubMed ID: 16229808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.